Nonhuman Animal Patents (Class 800/8)
  • Patent number: 10414812
    Abstract: The present invention relates to compositions and methods for treating HER2/Neu (ERBB2) expressing cancer cells. In some embodiments, the invention includes an isolated T cell receptor (TCR) having high affinity for and that specifically binds ERBB2369-377 epitope on a target cell. Other embodiments include a T cell or a population of T cells modified to express ERBB2-specific TCR. Further embodiments include methods of using ERBB2-specific TCR gene transfer for treating ERBB2 expressing cancer cells. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: September 17, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Daniel J. Powell, Jr.
  • Patent number: 10369210
    Abstract: The present invention provides cells which have a high ability to propagate influenza virus, are suitable for use in production of an influenza virus for preparing a vaccine, and are able to be cultured in vitro, and a method for producing an influenza virus using the cells. That is, the present invention provides cells for producing an influenza virus in which expression of one or more genes that encode proteins involved in an effect of suppressing influenza virus production in a cell is suppressed and the gene is at least one selected from the group including ACTG1 gene and the like, and a method for producing an influenza virus that includes infecting the cells for producing an influenza virus with an influenza virus and then culturing.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: August 6, 2019
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Yoshihiro Kawaoka, Tokiko Watanabe, Eiryo Kawakami, Shinji Watanabe
  • Patent number: 10302629
    Abstract: The present invention is drawn to therapeutics which can target hnRNP A18, a regulator of protein translation in cancer cells. The invention provides a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition that decreases the level and/or activity of heterogenous ribonucleoprotein A18 (hnRNP A18). The composition can comprise a nucleic acid molecule that binds to at least a portion of a nucleotide sequence coding for hnRNP A18. The invention also provides a composition for treating cancer comprising a nucleic acid or antibody that is capable of decreasing the level and/or activity of hnRNP A18 and a pharmaceutically acceptable carrier. The invention also provides methods of screening for an anti-cancer compound.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: May 28, 2019
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventor: France Carrier
  • Patent number: 10273457
    Abstract: A method of obtaining stromal progenitor cells (SPC) from subcutaneous adipose tissue by incubation of a very small volume of the subcutaneous adipose tissue in an enzyme solution produces SPC that are usable in medical applications based on autologous SPC even on individuals having a body mass index lower than 18.5.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: April 30, 2019
    Inventors: Massimo Dominici, Luigi Cafarelli, Elena Veronesi, Maria Serena Piccinno, Paolo Paolucci, Giorgio De Santis, Pierfranco Conte
  • Patent number: 10085465
    Abstract: The present invention is directed to isolated thraustochytrid microorganisms as well as strains and mutants thereof. The invention is further directed to biomasses, microbial oils, compositions, cultures, methods of producing microbial oils, and methods of using the isolated thraustochytrids, biomasses, and microbial oils.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: October 2, 2018
    Assignee: DSM IP Assets B.V.
    Inventors: Kirk E. Apt, Joseph W. Pfeifer, III, Jon Milton Hansen, Paul Warren Behrens, Ross Zirkle, Tracey Lynn Stahl
  • Patent number: 10087447
    Abstract: The invention provides an antibody specific to the ANGPTL4 protein capable of neutralizing proliferation and methods of making and using the same. The antibody of the invention is further directed to the C terminal region of the protein and may be capable of neutralizing cell proliferation and treating cancer. The antibody may be monoclonal and/or humanized antibody.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: October 2, 2018
    Assignee: Nanyang Technologies University
    Inventors: Nguan Soon Tan, Han Chung Chong, Ming Jie Tan, Royston Huang
  • Patent number: 10072251
    Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: September 11, 2018
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Li Zhong
  • Patent number: 10045516
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 14, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • Patent number: 9999206
    Abstract: Herein provided are a model and method for a transgenic a bovidae having an TGF-?1 gene inserted into the bovidae genome and capable of expressing higher than normal levels of TGF-?1 in cardiac muscle.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 19, 2018
    Assignee: Utah State University
    Inventors: Irina Polejaeva, Zhongde Wang, Shengwei Hu, Ravi Ranjan, Aaron James Thomas, Christopher Joseph Davies, Kenneth L. White
  • Patent number: 9987326
    Abstract: Disclosed is the use of a klotho protein or related compounds for the diagnosis and treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: June 5, 2018
    Assignees: Tel HaShomer Medical Research Infrastructure and Services Ltd., CEDARS-SINAI MEDICAL CENTER
    Inventors: H. Phillip Koeffler, Ido Wolf, Tamar Rubinek, Bella Kaufman, Lilach Abramovitch
  • Patent number: 9976122
    Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 22, 2018
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: David Spencer, Priyadharshini Narayanan
  • Patent number: 9974289
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 22, 2018
    Assignees: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • Patent number: 9957482
    Abstract: Methods and composition for the production of cardiomyocytes from differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including differentiating pluripotent stem cells in a large volume of suspension culture in the presence of ROCK inhibitors are described. In further aspects, methods for differentiation of stem cells into cardiomyocytes that overcome variability between different stem cell clones and different batch of culture medium are provided.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: May 1, 2018
    Assignee: Cellular Dynamics International, Inc.
    Inventors: Casey Stankewicz, Matt Riley, Nathaniel Beardsley, Wen Bo Wang, Peter Fuhrken, Steven Kattman
  • Patent number: 9931445
    Abstract: A system for extracting and processing adipose tissue to generate a therapeutically effective amount of adipose-derived stem cells, comprising an adipose tissue extraction device and a modified centrifuge tube comprising a plurality of lipoaspirate inlet fittings, a plurality of processing fluid inlet fittings, and a plurality of pellet extraction tubes. The adipose tissue extraction device is used to extract a quantity of adipose tissue from a human being, the lipoaspirate is moved into the first modified centrifuge tube via a sterile transfer, a plurality of processing steps are performed to clean and dissociate the lipoaspirate, and a pellet containing an enhanced fraction of stem cells is obtained by centrifuging the modified centrifugal tube. The pellet is resuspended in a fluid and administered to a human patient for a therapeutic or cosmetic purpose.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: April 3, 2018
    Assignee: JOINTECHLABS, INC.
    Inventors: Felix Pustilnik, Nathan Katz
  • Patent number: 9919031
    Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: March 20, 2018
    Assignee: THE BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS
    Inventors: Geoffrey Goldspink, Paul Goldspink
  • Patent number: 9848587
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: December 26, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Naxin Tu, Cagan Gurer
  • Patent number: 9816107
    Abstract: The present invention relates to methods of facilitating the expression of recombinant polypeptides from cells, extracellular fluids, extracellular fibers, or any combination thereof, obtained from transgenic insect cells and larvae comprising a bacterial GlcNAc-6-P 2?-epimerase (GNPE), which is capable of converting N-acetyl-D-glucosamine-6-phosphate (GlcNAc-6-P) to N-acetyl-D-mannosamine-6-phosphate (ManNAc-6-P). The invention relates to methods to promote efficient glycoconjugate sialylation, by providing simpler ways to produce large intracellular pools of sialic acid precursors. The invention is also directed to nucleic acids, vectors, and cells comprising nucleic acids encoding polypeptides involved in the synthesis of sialic acid precursors, and cells in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 14, 2017
    Assignee: The University of Wyoming
    Inventors: Christoph Geisler, Donald Jarvis
  • Patent number: 9605316
    Abstract: The present invention relates to methods and compositions for diagnosing a disease or disorder in a subject by introducing into cells of the subject a diagnostic gene switch construct and monitoring expression of a reporter gene. The invention further relates to methods and compositions for monitoring the progression of a disease or disorder or the effectiveness of a treatment for a disease or disorder.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: March 28, 2017
    Assignee: Intrexon Corporation
    Inventors: Robert P. Beech, Thomas D. Reed, Robert Patzig
  • Patent number: 9550078
    Abstract: The present invention relates to novel peptides derived from an EDAR (EDAR receptor) ligand which belongs to TNF (tumor necrosis factor)-? family and to uses of the same. The present peptides of EDA3 derived from EDA and EDphD1 derived from EDAR ligand possess identical or similar activities to naturally occurring EDA and have much higher stability and skin penetration potency than naturally occurring EDA. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss and promotion of hair growth, but also has superior efficacies on treatment of an EDA signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: January 24, 2017
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 9546376
    Abstract: A technique by which the production of plant biomass can be significantly increased is provided. A gene encoding protein phosphatase 2C having 3 consensus sequences comprising the amino acid sequences shown in SEQ ID NOS: 1-3 from the N-terminal side in such order and a gene encoding glutathione-binding plastid-type fructose 1,6-bisphosphate aldolase is introduced, or an expression control region of endogenous genes corresponding to the genes are modified.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: January 17, 2017
    Assignees: TOYOTA JIDOSHA KABUSHIKI KAISHA, OKAYAMA PREFECTURE
    Inventors: Satoshi Kondo, Chikara Ohto, Kenichi Ogawa, Norihiro Mitsukawa, Nobuhiko Muramoto, Tomoko Tanaka, Hiroki Sugimoto
  • Patent number: 9315825
    Abstract: The present invention relates to gene therapy systems designed for the delivery of a therapeutic product to a subject using replication-defective virus composition(s) engineered with a built-in safety mechanism for ablating the therapeutic gene product, either permanently or temporarily, in response to a pharmacological agent—preferably an oral formulation, e.g., a pill. The invention is based, in part, on the applicants' development of an integrated approach, referred to herein as “PITA” (Pharmacologically Induced Transgene Ablation), for ablating a transgene or negatively regulating transgene expression. In this approach, replication-deficient viruses are used to deliver a transgene encoding a therapeutic product (an RNA or a protein) so that it is expressed in the subject, but can be reversibly or irreversibly turned off by administering the pharmacological agent; e.g., by administration of a small molecule that induces expression of an ablator specific for the transgene or its RNA transcript.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: April 19, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M Wilson, Anna P Tretiakova, Jenny Agnes Greig
  • Patent number: 9247721
    Abstract: The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 2, 2016
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Markus Zweckstetter, Pinar Karpinar, Christian Griesinger
  • Patent number: 9220403
    Abstract: In accordance with an embodiment of the invention, there is provided a device and method for detecting an amyloid protein in an eye of a mammal. A method comprises illuminating the eye with a light source having at least one of a wavelength property, a polarization property or a combination thereof, each appropriate to produce fluorescence in at least an amyloid-binding compound when the amyloid-binding compound is bound to the amyloid protein, the amyloid-binding compound having been introduced to the eye and specifically binding to the amyloid protein indicative of the amyloidogenic disorder; and determining a time decay rate of fluorescence for at least the fluorescence produced by the amyloid-binding compound bound to the amyloid protein, the determining permitting distinguishing of the presence of the amyloid-binding compound bound to the amyloid protein in the eye based on at least the time decay rate.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: December 29, 2015
    Assignee: Cognoptix, Inc.
    Inventors: Paul D. Hartung, Vincent Valvo, Charles Kerbage, Gerald D. Cagle, Dennis J. Nilan
  • Patent number: 9155789
    Abstract: The present invention is directed to the discovery that allogenic or syngenic adjuvant stimulation can cause local inflammation which increases the antigen presentation capability of cells in the vicinity of adjuvant stimulation. By discovering this phenomenon, the present invention provides a novel method for augmenting the immunogencity of an antigen by conjointly administering an allogenic or syngenic MHC molecule (as a universal adjuvant) to trigger a local inflammatory reaction to enhance antigen presentation at the site of delivery.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: October 13, 2015
    Assignee: NEW YORK UNIVERSITY
    Inventor: Moriya Tsuji
  • Patent number: 9133263
    Abstract: The invention relates to a cell containing a gene encoding a conditional transgenic surface marker that is detectable upon expression on the surface of the cell, wherein the gene encoding a conditional transgenic surface marker comprises: (i) a promoter, operably linked to (ii) a first transcription sequence, and (iii) a second transcription sequence encoding the surface marker, whereby the first transcription sequence prevents the transcription of the second transcription sequence, whereby the first transcription sequence is conditionally removable such that the second transcription sequence is transcribable, and whereby the surface marker renders the cell sortable through the detection of the conditional transgenic surface marker. Furthermore, the invention relates to a construct for generating such a cell, and to a method for separating such a cell from a population of cells.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: September 15, 2015
    Assignee: MILTENYI BIOTEC GMBH
    Inventor: Andreas Bosio
  • Patent number: 9125385
    Abstract: The present disclosure provides a method of making a mammal (e.g., a rodent, such as a mouse) by integrating an intact polynucleotide sequence into a specific genomic locus of the mammal to result in a transgenic mammal. A transgenic mammal made by the methods of the present disclosure would contain a known copy number (e.g., one) of the inserted polynucleotide sequence at a predetermined location. The method involves introducing a site-specific recombinase and a targeting construct, containing a first recombination site and the polynucleotide sequence of interest, into the mammalian cell. The genome of the cell contains a second recombination site and recombination between the first and second recombination sites is facilitated by the site-specific, uni-directional recombinase. The result of the recombination is site-specific integration of the polynucleotide sequence of interest in the genome of the mammal. This inserted sequence is then also transmitted to the progeny of the mammal.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: September 8, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Liqun Luo, Ruby Yanru Tsai, Bosiljka Tasic, Simon Hippenmeyer, Hui Zong
  • Patent number: 9113616
    Abstract: The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: August 25, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, John McWhirter, Naxin Tu, Vera Voronina, Cagan Gurer, Karolina Meagher, Sean Stevens
  • Patent number: 9109045
    Abstract: The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media and conditions. Also, stem cell culture media produced according to the method of the invention, and human growth factors isolated from the culture media, can be advantageously used as raw materials for drugs and cosmetics.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: August 18, 2015
    Assignees: PROSTEMICS CO., LTD.
    Inventors: ByungSoon Park, BongGeun Choi, ChulHong Park
  • Patent number: 9103790
    Abstract: A linker for a unimolecular FRET biosensor based on a principle of fluorescence resonance energy transfer, the linker including: a polypeptide containing 52 to 400 amino acids residues, wherein at least 45% of a total number of the amino acid residues are glycine, alanine, or both thereof, and at least 10% of the total number of the amino acid residues are alanine.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 11, 2015
    Assignee: KYOTO UNIVERSITY
    Inventors: Michiyuki Matsuda, Naoki Komatsu, Kazuhiro Aoki, Yuji Kamioka, Hiroko Yukinaga, Yoshie Inaoka, Atsuro Sakurai, Etsuko Kiyokawa, Kenta Sumiyama
  • Patent number: 9060498
    Abstract: Provided is a pterygium animal model produced by injecting human-derived pterygial epithelial cells that are isolated and cultured in vitro. The animal model has characteristics similar to those of pterygium, which are observed only in humans, wherein such characteristics are caused in such a way that pterygial epithelial cells are isolated from human pterygium corneal tissues and cultured, the cultured pterygial epithelial cells are sub-cultured, and human-derived pterygial epithelial cells of which identify is confirmed are injected into the nasal subconjunctival space of mice. The pterygium animal model allows a pterygium therapeutic agent to be effectively screened.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: June 23, 2015
    Assignee: INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Jae Wook Yang, Hye Sook Lee, Ji Hyun Lee
  • Patent number: 9045793
    Abstract: The present invention relates to a method of regulating the expression level of survival of motor neuron 1 (SMN1) comprising administering to a subject in need thereof a therapeutically effective amount of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulator and a pharmaceutically acceptable carrier. The present invention also relates to a method of detecting enzyme activity of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) in human fibroblasts comprising detecting protein expression level of survival of motor neuron 1 (SMN1).
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: June 2, 2015
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yuh-Jyh Jong, Shih-Hsien Hsu, Jan-Gowth Chang
  • Publication number: 20150150152
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • Publication number: 20150150151
    Abstract: A method of growing shellfish is disclosed. The method comprises obtaining a support tray (I) with recesses (7) where at least some of the recesses (7) incorporate means adapted to create a deliberately formed alphanumeric, written or pictorial mark on the shellfish as it grows. Shellfish spat are attached to at least some of the recesses (7) and the tray (I) is placed in water so that the spat grow into substantially mature shellfish within the recesses (7). The spat each grow generally in the shape of their respective recess (7) so that the mark is created on the shellfish as it grows.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 28, 2015
    Inventor: Shaun Gregory
  • Patent number: 9040771
    Abstract: Provided herein are mitochondrial-nuclear exchanged cells and animals comprising mitochondrial DNA (mtDNA) from one subject and nuclear DNA (nDNA) from a different subject. Methods for producing a mitochondrial-nuclear exchanged animal and animals made by the methods are provided. Also provided are methods of screening for agents useful for treating a disease or disorder using mitochondrial-nuclear exchanged animals or cells, tissues or organs thereof.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: May 26, 2015
    Assignee: The UAB Research Foundation
    Inventors: Scott Webster Ballinger, Danny R. Welch, Robert Allen Kesterson, Larry W. Johnson
  • Publication number: 20150143555
    Abstract: This invention is directed to the composition, method of production, aid rrse of improved edible fish, crustacean, or mollusk products enriched with one or more components that provide health benefits to humans or other animals consuming the product.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 21, 2015
    Applicant: ADVANCED BIONUTRITION CORPORATION
    Inventors: David J. KYLE, Moti HAREL, John PIECHOCKI
  • Publication number: 20150132322
    Abstract: This invention provides a human antibody, a hybridoma cell line for the production of the antibody, a reconstituted mouse strain for the production of the hybridoma, and methods of producing and using thereof.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Inventors: Jean Elie Kadouche, Alain Razafindrastita
  • Patent number: 9018441
    Abstract: Hairless, immunodeficient mice on a non-obese diabetic (NOD) background and methods for their production are disclosed herein. The mice are hairless and have multiple immunodeficiencies, including B-cell and T-cell deficiencies, as well as impaired macrophage and complement function. The mice also have a further deficit in natural killer and dendritic cells of the immune system. The mice are useful for biomedical research, for example, in studies involving xenograft transplantation, spontaneous tumors, cancer cell tumorigenesis, tumor angiogenesis, tumor metastatic potential, tumor suppression therapy, carcinogenesis regulation, and tumor imaging.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 28, 2015
    Assignee: Harlan Laboratories, Inc.
    Inventor: Sheryl Wildt
  • Publication number: 20150113671
    Abstract: The present invention relates to nucleic acids encoding peptides capable of binding to actin. The nucleic acids encoding the peptides are useful in methods for detecting actin in vitro or in living cells.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 23, 2015
    Inventors: Roland Wedlich-Soldner, Michael Sixt, Julia Riedl, Alvaro Crevenna
  • Publication number: 20150113670
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
  • Publication number: 20150106959
    Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.
    Type: Application
    Filed: May 19, 2014
    Publication date: April 16, 2015
    Inventors: Carol J. Phelps, David L. Ayares
  • Patent number: 8993833
    Abstract: A modified non-human warm-blooded vertebrate animal in which a biologically active human APP polypeptide is expressed, and in which function of its inducible Nitric Oxide Synthase (iNOS) protein is reduced as compared to a non-modified animal, methods of making the animal, and methods of testing a candidate composition for activity in the treatment of Alzheimer's Disease using the animal.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: March 31, 2015
    Assignee: Duke University
    Inventors: Carol Anne Colton, Michael Peter Vitek, Judianne Davis, William E. VanNostrand
  • Patent number: 8981179
    Abstract: The present invention relates generally to transgene constructs, transgenic non-human animals comprising transgene constructs, methods of making and methods of using the transgenic non-human animals comprising transgene constructs. An embodiment of the invention relates to methods of assaying the activation of GPCR ligands non-invasively in whole animals, tissue slices, or in native cells using a transgenic model containing a bioluminescent transgene reporter system that is responsive to pathway modulation following ligand binding of GPCR receptors.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: March 17, 2015
    Assignee: Sanofi
    Inventors: Holly Dressler, Kyriakos D. Economides, Zhen Pang, Harry Gregory Polites
  • Patent number: 8957279
    Abstract: The present invention relates to a novel mite composition comprising a population of a phytoseiid predatory mite species and a factitious host population comprising a species selected from the Glycyphagidae, which may be employed for rearing said phytoseiid predatory mite species or for releasing the phytoseiid predatory mite species in a crop. According to further aspects the invention relates to a method for rearing a phytoseiid predatory mite species, to the use of the mite composition and to a method for biological pest control in a crop, which employ the mite composition.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: February 17, 2015
    Assignee: Koppert B.V.
    Inventors: Karel Jozef Florent Bolckmans, Yvonne Maria Van Houten, Adelmar Emmanuel Van Baal, Marisa Castagnoli, Roberto Nannelli, Sauro Simoni
  • Patent number: 8952214
    Abstract: A nonhuman transgenic mammal is described whose genome comprises a promoter construct operably linked to a heterologous DNA encoding an epithelial sodium channel ? subunit, wherein said promoter construct directs expression of the epithelial sodium channel ? subunit in lung epithelial cells of said animal, and wherein said transgenic mammal has increased lung mucus retention as compared to the corresponding wild-type mammal. The animal is useful in screening compounds for activity in treating lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: February 10, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Richard C. Boucher, Jr., Wanda O'Neal, Barbara Grubb, Marcus Mall
  • Publication number: 20150040251
    Abstract: The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.
    Type: Application
    Filed: February 4, 2013
    Publication date: February 5, 2015
    Inventors: Jacqueline Matthews, Alasdair Justice Nisbet, David Knox
  • Patent number: 8937213
    Abstract: Systems and methods relate to transgenic organisms and their use as biosensors are described. In some embodiments, the systems and methods include a first population of transgenic organisms that includes a first constitutively expressed reporter gene, and a first transgene that includes a first inducible promoter from a response pathway gene, wherein the first inducible promoter is coupled to a first reporter gene. Other embodiments are described.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: January 20, 2015
    Inventors: Christopher E. Hopkins, Miluka Gunaratna
  • Publication number: 20150007358
    Abstract: Described herein are methods and compositions for modulating bovine birth rate by following a breeding scheme based on the presence of the trio haplotype, which is strongly linked to the propensity to give birth to multiple calves in one event.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventor: Brian Wayne Kirkpatrick
  • Publication number: 20140351963
    Abstract: Disclosed are compositions, such as nucleic acids, vectors, cells, animal models and the like, useful to reduce tumor growth, cancer cell migration and various other cancer pathologies associated with EGFR (epidermal growth factor receptor) and MET (the receptor tyrosine kinase for hepatocyte growth factors) dyregulation, particularly in non-small cell lung carcinoma.
    Type: Application
    Filed: December 10, 2012
    Publication date: November 27, 2014
    Applicant: OHIO STATE INNOVATION FOUNDATION
    Inventors: Carlo M. Croce, Michela Garofalo
  • Publication number: 20140351961
    Abstract: Disclosed are methods and compositions for treating cancer that involved an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of Hsp-27.
    Type: Application
    Filed: August 30, 2012
    Publication date: November 27, 2014
    Inventor: Alexzander A. Asea
  • Patent number: RE46642
    Abstract: An isolated sucrose synthase peptide. Also, a method of preparing ADPglucose by incubating the isolated sucrose synthase peptide with ADP in suitable conditions and then isolating and purifying the ADPG produced. Also, an assay kit for the spectrophotometric, fluorimetric or amperometric determination of sucrose, which kit includes the isolated sucrose synthase peptide. Also, a method of producing a transgenic plant that overexpresses sucrose synthase by inserting a genetic construct containing a DNA fragment that encodes the sucrose synthase peptide into a vector and transferring to a plant genome, and a transgenic plant obtained thereby.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: December 19, 2017
    Assignees: UNIVERSIDAD PUBLICA DE NAVARRA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Miren Edurne Baroja Fernandez, Francisco José Muñoz Perez, Francisco Javier Pozueta Romero, Maria Teresa Moran Zorzano, Nora Alonso Casajus